Reported Earlier, Lycia Therapeutics Prices Upsized Initial Public Offering Of 17.64M Shares At $18.00 Each For Expected $317.5M Gross Proceed
Share
Why It Matters
Lycia Therapeutics sold more shares than planned in their first stock sale. This shows investors believe in the company and want to own a piece of it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.